Holy Stone Health Care Unveils HylX drug delivery technology platform at SDDS 2025 with Multi-Organ Targeting Capabilities

Kobe, Japan-May 14. 2025 -Holy Stone Health Care (HSHC) presented its proprietary HylX drug delivery technology platform at the 12^th international Symposium of Drug Delivery System (SDDS 2025). The SDDS conference is an important global venue for showcasing breakthrough innovations in drug delivery technology.

During an invited oral presentation, CSO Dr. Charles Hou unveiled the HylX platform utilizing tailored Hylauronic acid(HA)-based smart carrier technology capable of traversing key biological barrier. These novel technologies are designed to enhance payload retention, target specificity, and reduce system exposure.

Key HylX technology and assets including:

1. HylNeuro™ : CNS-targeted delivery across BBB for neurodegeneration. The lead candidate ND108E has demonstrated effective BBB penetration and hippocampal targeting in preclinical Alzheimer’s disease models.
2. HylTargis™ : CD44-targeted drug carrier that can penetrate tumor stroma. CA102N, the first-in-class candidate, has completed Phase I clinical trial with strong safety profile in metastatic colorectal cancer (mCRC), and is positioned for expansion into pancreatic ductal adenocarcinoma (PDAC)   
3. HylMusa™ : Mucosal healing and anti-inflammation in gastrointestinal tract. In Phase IIa clinical studies, IBD98-M demonstrated anti-inflammatory drug (5-ASA) can be encapsulated inside HA, delivered to the mucosal inflammation sites of colon, and enhanced mucosa healing in ulcerative colitis patients.
4. HylRetinX™ : Oral drug delivery across BRB for retinal diseases. AMD112 was currently in preclinical development for wet age-related macular degeneration (wet AMD)
5. HylCaryo™ – A non-lipid HA–based nanoparticle delivery technology for RNA/nucleic acid with selective cellular uptake.

Participation SDDS 2025 marks a key milestone in HSHC to strength its global R&D network in innovative drug delivery technology, and promote the HylX drug delivery technology platform and related assets.